logo ecco

logo ecco

Portal
  • About ECCO
    • General Assembly
    • Governing Board
    • Committees / Operational Board
    • The Council of National Representatives
    • Collaborations
    • Solidarity for Ukraine
    • Elections
    • Community Videos
    • Affiliate Societies & Partners
    • Y-ECCO Contributors
    • ECCO Office
    • ECCO Disclosures
    • REACH
    • Diversity, Equity & Inclusion
  • Congresses & Events
    • Upcoming
      • 21st Congress of ECCO 2026 - Stockholm
    • Past
      • 20th Congress of ECCO 2025 - Berlin
      • 19th Congress of ECCO 2024 - Stockholm
    • Event Calendar
    • Congress Statistics
    • Quality Assurance/Endorsement
  • Membership
    • Individual Membership
    • Country Members
    • Corporate Membership
    • Affiliate ECCO Societies
  • Education
    • E-QUALITY
    • e-Learning
    • Letters from the e-Learning Editor-in-Chief
    • Educational Workshops
    • Congress Educational Programme
    • IBD Nurse Education Programme
    • Y-ECCO Mentorship Forum
    • Fast Facts in IBD
  • Science
    • UR-CARE
    • The Reviewers of ECCO
    • The Reviewers of 2024
    • Fellowships, Grants & Awards
    • ECCO Young Researcher Award
    • Scientific Workshops
    • Research Projects
    • ECCO CONFER Cases
  • Publications
    • JCC
    • JCC Plus
    • JCC on X/Twitter
    • Guidelines
    • Topical Review
    • Position Statements
    • Scientific Workshop Papers
    • ECCO News
    • ECCO IBD App
    • Congress Abstracts
    • Surveys
    • Other publications
    • eNewsletter

ECCO'25 Abstracts

ECCO'25 Abstracts on the JCC Website

ECCO'25 Abstract Book PDF Version

ECCO'25 Abstracts COI Disclosure

ECCO'24 Abstracts

ECCO'24 Abstracts on the JCC Website

ECCO'24 Abstract Book PDF Version

ECCO'24 Abstracts COI Disclosure

Poster presentations: Clinical: Therapy and Observation 2022

P479 Trends in medication use and treatment patterns in Chinese patients with Inflammatory Bowel Diseases: A multicenter cohort study from 1999 to 2020

Yao, L.(1);Shao, B.(1);Cao, Q.(1);

(1)Sir Run Run Shaw Hospital- College of Medicine Zhejiang University, Department of Gastroenterology, Hangzhou, China;

Background

The temporal changes in medication use and therapeutic paradigm in patients with Inflammatory bowel disease (IBD) have not been well elucidated in China over the past two decades. Therefore, we aimed to identify the temporal changes in medication use and treatment patterns for Chinese patients with IBD and to evaluate the factors associated with initial drug strategies.

Methods

A multicenter retrospective cohort study was conducted among Chinese patients newly diagnosed with Crohn’s disease (CD) and ulcerative colitis (UC) from January 1999 to December 2019. Medication utilization, treatment patterns, and associated factors with initial drug strategies were investigated.

Results

Prescriptions of 5-aminosalicylates (ASA) and corticosteroids (CS) gradually decreased, whereas prescriptions of immunosuppressants (IMS) and infliximab (IFX) increased in patients with CD. Except for stable prescriptions of ASA and CS, IMS and IFX increased since 2007 in patients with UC. Subgroup (N=957) analyses revealed that treatment patterns went through notable changes from ASA to IMS or IFX in patients with CD, while ASA and CS were still steadily prescribed in patients with UC. Logistic regression analyses revealed that perianal and gastrointestinal surgeries before diagnosis, disease behavior, and disease location were associated with different initial therapeutic strategies in patients with CD. However, medications before diagnosis, disease location, and diagnostic year might affect initial strategies in patients with UC.

Conclusion

Parallel to increasing uses of IMS and IFX in IBD over past two decades, a significant decrease in uses of ASA and CS were observed in CD, but not in UC. Treatment strategies analyses provided a unique insight in understanding long-term therapeutic patterns in the Chinese population.

  • Posted in: Poster presentations: Clinical: Therapy and Observation 2022
Logo_contact.png     T: +43 (0)1 710 22 42-0
F: +43 (0)1 710 22 42-001
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Home
  • Sitemap
  • Contact
  • Imprint
  • Data privacy statement
  • Media Policy

  • About ECCO
    • General Assembly
    • Governing Board
    • Committees / Operational Board
    • The Council of National Representatives
    • Collaborations
    • Solidarity for Ukraine
    • Elections
    • Community Videos
    • Affiliate Societies & Partners
    • Y-ECCO Contributors
    • ECCO Office
    • ECCO Disclosures
    • REACH
    • Diversity, Equity & Inclusion
  • Congresses & Events
    • Upcoming
      • 21st Congress of ECCO 2026 - Stockholm
    • Past
      • 20th Congress of ECCO 2025 - Berlin
      • 19th Congress of ECCO 2024 - Stockholm
    • Event Calendar
    • Congress Statistics
    • Quality Assurance/Endorsement
  • Membership
    • Individual Membership
    • Country Members
    • Corporate Membership
    • Affiliate ECCO Societies
  • Education
    • E-QUALITY
    • e-Learning
    • Letters from the e-Learning Editor-in-Chief
    • Educational Workshops
    • Congress Educational Programme
    • IBD Nurse Education Programme
    • Y-ECCO Mentorship Forum
    • Fast Facts in IBD
  • Science
    • UR-CARE
    • The Reviewers of ECCO
    • The Reviewers of 2024
    • Fellowships, Grants & Awards
    • ECCO Young Researcher Award
    • Scientific Workshops
    • Research Projects
    • ECCO CONFER Cases
  • Publications
    • JCC
    • JCC Plus
    • JCC on X/Twitter
    • Guidelines
    • Topical Review
    • Position Statements
    • Scientific Workshop Papers
    • ECCO News
    • ECCO IBD App
    • Congress Abstracts
    • Surveys
    • Other publications
    • eNewsletter